Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib THEN
NCT02876081Phase 2Withdrawn
- Sponsor
- Fondation Hôpital Saint-Joseph
- Start
- Sep 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of afatinib in lung adenocarcinoma, sponsored by Fondation Hôpital Saint-Joseph. Primary endpoint: Disease Control Rate at 2 months. Planned start Sep 2017; status: withdrawn.
02
Drugs
afatinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02876081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876081.